Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Retained Earnings (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Retained Earnings for 13 consecutive years, with -$164.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Retained Earnings rose 9.56% to -$164.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$164.5 million, a 9.56% increase, with the full-year FY2025 number at -$164.5 million, up 9.56% from a year prior.
  • Retained Earnings was -$164.5 million for Q4 2025 at Niagen Bioscience, up from -$168.7 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$154.8 million in Q2 2021 to a low of -$191.0 million in Q2 2024.
  • A 5-year average of -$179.5 million and a median of -$183.1 million in 2022 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: dropped 19.13% in 2021, then grew 10.8% in 2025.
  • Niagen Bioscience's Retained Earnings stood at -$169.0 million in 2021, then fell by 9.79% to -$185.5 million in 2022, then dropped by 2.68% to -$190.5 million in 2023, then rose by 4.49% to -$181.9 million in 2024, then increased by 9.56% to -$164.5 million in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Retained Earnings are -$164.5 million (Q4 2025), -$168.7 million (Q3 2025), and -$173.2 million (Q2 2025).